Trial
NCT07693374
Chinese Medicinal Component Relieves CIPN and Mitochondria Function
UnknownWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Taiwan Municipal An-Nan Hospital-China Medical University
Collaborators
China Medical University, Taiwan
Condition
Breast Cancer
Intervention
Moutan cortex
Why stopped
Initial prep showed that formulation, QC, and cost for high-dose paeonol/Cortex Moutan exceeded the budget. Also, recruiting patients with chemotherapy-induced peripheral neuropathy was limited. To ensure safety, enrollment did not officially launch.
Provenance
Dataset: 2026-07-10 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-09